Investor Presentation H1 2023

55 Investor presentation First six months of 2023 Once-weekly Insulin icodec, a basal insulin intended for once- weekly treatment, may reduce the disease burden for patients Bringing the strongest value proposition to market Insulin icodec phase 3 programme has been completed 984 people insulin-naïve, 78-week, vs insulin glargine U100 TIR: Time-in-range ONWARDS 1 Reduction of disease burden with once-weekly treatment ONWARDS 2 526 people on basal, 26-week, vs insulin degludec Tested for superior HbA1c and TiR vs glargine and standard-of-care and ONWARDS 3 588 people insulin-naïve, 26-week, vs insulin degludec similar safety profile of Tresiba® ONWARDS 4 582 people on both basal and bolus, 26-week, vs insulin degludec App-based offering and connected smart pen to optimise titration and support compliance and data collection ONWARDS 5 1,085 people, insulin-naïve using app-based dosing recommendations, 52-week ONWARDS 6 582 people, type 1 diabetes using bolus insulin, 52-week, vs insulin degludec Reduced environmental footprint Submission Insulin Icodec has been submitted in US, EU and China in Q2 2023 Novo NordiskⓇ

View entire presentation